Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
No te pierdas la II edición RESPrimaria el próximo 7 de mayo. Inscríbete en formato Streaming o solicita tu invitación presencial. ¡Plazas limitadas!
Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.
Climate change and COPD are linked through extreme temperature, wildfire smoke, dust storms and allergen exposure, which pose major health threats.
Airway mucous plugging is associated with exacerbations, lung function decline, and mortality in COPD, asthma, and bronchiectasis. Identifying it as a treatable trait may improve patient outcomes through airway clearance techniques and pharmacological strategies.
Descubre los avances en el diagnóstico y tratamiento de la EPOC con el Dr. Alvar Agustí en la II Jornada SEMG Resprimaria. Conoce la importancia de la espirometría, la detección precoz y las nuevas estrategias terapéuticas.
